ArticleClinical and molecular hepatology2022
Surveillance for hepatocellular carcinoma: It is time to move forward.
Article in Clinical and molecular hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- SF3B4 stabilizes SREBF1 via 3'UTR binding to drive hepatocellular carcinoma progression.Frontiers in oncology · 2026Article
- METTL1-driven nucleotide metabolism reprograms the immune microenvironment in hepatocellular carcinoma: a multi-omics approach for prognostic biomarker discovery.Frontiers in immunology · 2025Article
- Article
- Clinical practice guidelines and real-world practice for hepatocellular carcinoma in Taiwan: Bridging the gap.Clinical and molecular hepatology · 2023Article
- The prime time for management of hepatocellular carcinoma in Hong Kong.Clinical and molecular hepatology · 2023Article
- What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea?Clinical and molecular hepatology · 2023Article
- Correspondence on Editorial regarding "Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease".Clinical and molecular hepatology · 2023Article
Corrections and comments
- Commented on by
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.